Antiatherothrombotic effects of dipeptidyl peptidase inhibitors

Current Atherosclerosis Reports

Volumn 16, Issue 5, 2014, Pages

  Cameron Vendrig, Alison ^a,b   Mundil, Dhanwantee ^a,c   Husain, Mansoor ^a,c,d  

^a UNIVERSITY HEALTH NETWORK   (Canada)

^b ST MICHAEL'S HOSPITAL   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d HEART AND STROKE FOUNDATION OF CANADA   (Canada)

Author keywords

Atherosclerosis; Atherothrombosis; Cardiovascular; Dipeptidyl peptidase 4; Glucagon like peptide 1; Heart failure; Incretin; Myocardial infarction; Stroke; Thrombotic event

Indexed keywords

ALOGLIPTIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENALAPRIL; GLIBENCLAMIDE; GLIMEPIRIDE; HEMOGLOBIN A1C; LINAGLIPTIN; LOW DENSITY LIPOPROTEIN; METFORMIN; PLACEBO; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TRIACYLGLYCEROL; VILDAGLIPTIN; VOGLIBOSE; ANTIDIABETIC AGENT; INCRETIN;

ADVERSE OUTCOME; ANTIATHEROTHROMBOTIC ACTIVITY; ARTICLE; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; DIASTOLIC BLOOD PRESSURE; DRUG ACTIVITY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; HEART INFARCTION; HUMAN; HYPERTENSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OUTCOME ASSESSMENT; PATIENT SAFETY; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE FUNCTION; TREATMENT DURATION; UNSTABLE ANGINA PECTORIS; ANIMAL; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; METABOLISM;

ANIMALS; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INCRETINS;

EID: 84895776483     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-014-0408-2     Document Type: Article

References (61)

1. Stary HC et al. A definition of initial, fatty streak, and intermediate lesions of atherosclerosis. A report fromthe Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association. Circulation. 1994;89(5):2462-78. (Pubitemid 24142837)
2. McNeill AM et al. The metabolic syndrome and 11-year risk of incident cardiovascular disease in the Atherosclerosis Risk in Communities study. Diabetes Care. 2005;28(2):385-90. (Pubitemid 40170944)
3. Steinberg HO et al. Obesity/insulin resistance is associated with endothelial dysfunction. Implications for the syndrome of insulin resistance. J Clin Invest. 1996;97(11):2601-10.
4. UK Prospective Diabetes Study (UKPDS) Group. Intensive bloodglucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837-53.
5. Aronoff S et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care. 2000;23(11):1605-11.
6. Yousefzadeh P, Wang X. The effects of dipeptidyl peptidase-4 inhibitors on cardiovascular disease risks in type 2 diabetes mellitus. J Diabetes Res. 2013;2013:459821.
7. Mundil D, Cameron-Vendrig A, Husain M. GLP-1 receptor agonists: a clinical perspective on cardiovascular effects. Diabetes Vasc Dis Res. 2012;9(2):95-108.
8. Alexander RW. Theodore Cooper Memorial Lecture. Hypertension and the pathogenesis of atherosclerosis. Oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension. 1995;25(2):155-61.
9. Ferreira L et al. Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat). Mediat Inflamm. 2010;2010:592760.
10. Abd El Motteleb DM, Elshazly SM. Renoprotective effect of sitagliptin against hypertensive nephropathy induced by chronic administration of L-NAME in rats: role of GLP-1 and GLP-1 receptor. Eur J Pharmacol. 2013;720(1-3):158-65.
11. Mistry GC et al. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on blood pressure in nondiabetic patients with mild to moderate hypertension. J Clin Pharmacol. 2008;48(5):592-8. (Pubitemid 351503521)
12. Marney A et al. Interactive hemodynamic effects of dipeptidyl peptidase-IV inhibition and angiotensin-converting enzyme inhibition in humans. Hypertension. 2010;56(4):728-33.
13. Scirica BM, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369(14):1317-26.
14. Ogawa S et al. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, decreases systolic blood pressure in Japanese hypertensive patients with type 2 diabetes. Tohoku J Exp Med. 2011;223(2):133-5.
15. Kubota A et al. Pleiotropic effects of sitagliptin in the treatment of type 2 diabetes mellitus patients. J Clin Med Res. 2012;4(5):309-13.
16. Jagla A, Schrezenmeir J. Postprandial triglycerides and endothelial function. Exp Clin Endocrinol Diabetes. 2001;109(4):S533-47. (Pubitemid 32577696)
17. Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab. 2009;5(3):150-9.
18. Matikainen N et al. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia. 2006;49(9):2049-57. (Pubitemid 44168471)
19. Boschmann M et al. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. J Clin Endocrinol Metab. 2009;94(3):846-52.
20. Tremblay AJ et al. Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13(4):366-73.
21. Eliasson B et al. Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study. Diabetologia. 2012;55(4):915-25.
22. Plutzky J, Viberti G, Haffner S. Atherosclerosis in type 2 diabetes mellitus and insulin resistance: mechanistic links and therapeutic targets. J Diabetes Complicat. 2002;16(6):401-15. (Pubitemid 35449086)
23. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation. 2002;105(9):1135-43. (Pubitemid 34212626)
24. Alexandraki K et al. Inflammatory process in type 2 diabetes: the role of cytokines. Ann N Y Acad Sci. 2006;1084:89-117. (Pubitemid 47091972)
25. Sjoholm A, Nystrom T. Inflammation and the etiology of type 2 diabetes. Diabetes Metab Res Rev. 2006;22(1):4-10. (Pubitemid 43154455)
26. Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98-107.
27. Gorrell MD, Gysbers V, McCaughan GW. CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes. Scand J Immunol. 2001;54(3):249-64. (Pubitemid 34205737)
28. White PC, Chamberlain-Shea H, de la Morena MT. Sitagliptin treatment of patients with type 2 diabetes does not affect CD4+ Tcell activation. J Diabetes Complicat. 2010;24(3):209-13.
29. Matsubara J et al. Dipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its antiinflammatory effects in patients with coronary artery disease and uncontrolled diabetes. Circ J. 2013;77(5):1337-44.
30. Lee SA et al. CD26/DPP4 levels in peripheral blood and T cells in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab. 2013;98(6):2553-61.
31. Shah Z et al. Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis. Circulation. 2011;124(21):2338-49.
32. Dobrian AD et al. Dipeptidyl peptidase IV inhibitor sitagliptin reduces local inflammation in adipose tissue and in pancreatic islets of obese mice. Am J Physiol Endocrinol Metab. 2011;300(2): E410-21.
33. Shirakawa J et al. Diet-induced adipose tissue inflammation and liver steatosis are prevented by DPP-4 inhibition in diabetic mice. Diabetes. 2011;60(4):1246-57.
34. -/- mice. Diabetologia. 2012;55(8):2267-75.
35. Noyan-Ashraf MH et al. A glucagon-like peptide-1 analog reverses the molecular pathology and cardiac dysfunction of a mouse model of obesity. Circulation. 2013;127(1):74-85.
36. Dokken BB et al. Oxidative stress-induced insulin resistance in rat skeletal muscle: role of glycogen synthase kinase-3. Am J Physiol Endocrinol Metab. 2008;294(3):E615-21. (Pubitemid 351355233)
37. Shah Z, et al. Acute DPP-4 inhibition modulates vascular tone through GLP-1 independent pathways. Vasc Pharmacol. 2011;55(1-3):2-9.
38. Mason RP et al. Effect of enhanced glycemic control with saxagliptin on endothelial nitric oxide release and CD40 levels in obese rats. J Atheroscler Thromb. 2011;18(9):774-83.
39. Liu L et al. Dipeptidyl peptidase 4 inhibitor sitagliptin protects endothelial function in hypertension through a glucagon-like peptide 1-dependent mechanism. Hypertension. 2012;60(3):833-41.
40. Krijnen PA et al. Loss of DPP4 activity is related to a prothrombogenic status of endothelial cells: implications for the coronary microvasculature of myocardial infarction patients. Basic Res Cardiol. 2012;107(1):233.
41. Ayaori M et al. Dipeptidyl peptidase-4 inhibitors attenuate endothelial function as evaluated by flow-mediated vasodilatation in type 2 diabetic patients. J Am Heart Assoc. 2013;2(1):e003277.
42. Vinik AI et al. Platelet dysfunction in type 2 diabetes. Diabetes Care. 2001;24(8):1476-85. (Pubitemid 33716440)
43. Schneider DJ. Factors contributing to increased platelet reactivity in people with diabetes. Diabetes Care. 2009;32(4):525-7.
44. 2+ homeostasis in diabetes mellitus. Am J Physiol Heart Circ Physiol. 2001;280(4):H1480-9.
45. Angiolillo DJ et al. Impact of platelet reactivity on cardiovascular outcomes in patients with type 2 diabetes mellitus and coronary artery disease. J Am Coll Cardiol. 2007;50(16): 1541-7. (Pubitemid 47532327)
46. Cameron-Vendrig A, Reheman A, Afroze T, Noyan-Ashraf MH, Ni H, Husain M. Abstract 18777: glucagon-like peptide-1 inhibits thrombin-induced human platelet aggregation. Circulation. 2012;126, A18777.
47. Gupta AK et al. Sitagliptin: anti-platelet effect in diabetes and healthy volunteers. Platelets. 2012;23(8):565-70.
48. Gallwitz B, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, noninferiority trial. Lancet. 2012;380(9840):475-83.
49. Johansen OE et al. Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme. Cardiovasc Diabetol. 2012;11:3.
50. Gitt AK et al. Prognostic implications of DPP-4 inhibitor vs. sulfonylurea use on top of metformin in a real world setting - results of the 1 year follow-up of the prospective DiaRegis registry. Int J Clin Pract. 2013;67(10):1005-14.
51. Monami M et al. Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab. 2013;15(2):112-20.
52. Frederich R et al. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgrad Med. 2010;122(3):16-27.
53. Williams-Herman D et al. Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes. BMC Endocr Disord. 2010;10:7.
54. Engel SS et al. Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis. Cardiovasc Diabetol. 2013;12:3.
55. Scheller NM et al. All-cause mortality and cardiovascular effects associated with the DPPIV-inhibitor sitagliptin compared with metformin, a retrospective cohort study on the Danish population. Diabetes Obes Metab. 2014;16(3):231-6.
56. White WB et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327-35.
57. Merck Sharp & Dohme. Sitagliptin Cardiovascular Outcome Study (MK-0431-082) (TECOS). National Library of Medicine. 2008-2014. http://clinicaltrials.gov/show/NCT00790205 NLM Identifier: NCT00790205. Accessed 14 Jan 2014.
58. Boehringer Ingelheim Pharmaceuticals. CAROLINA: Cardiovascular Outcome Study of Linagliptin Versus Glimepiride in Patients with Type 2 Diabetes. National Library of Medicine. 2010-2014. http://clinicaltrials.gov/show/ NCT01243424 NLM Identifier: NCT01243424. Accessed 14 Jan 2014.
59. Oslo University Hospital. Saxagliptin and Atherosclerosis (SAXATH). National Library of Medicine. 2012. http://clinicaltrials.gov/show/NCT01552018 NLM Identifier: NCT01552018. Accessed 14 Jan 2014.
60. Sheba Medical Center. Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetics with Coronary Artery Disease (VAAST). National Library of Medicine. 2012-2013. http://clinicaltrials.gov/show/NCT01604213 NLM Identifier: NCT01604213. Accessed 14 Jan 2014.
61. Bristol-Meyers Squibb. Risk of Cardiovascular Events in Patients with Type 2 Diabetes Initiating Oral Antidiabetic Treatments. National Library of Medicine (US). 2010-2012. http://clinicaltrials.gov/show/NCT01086280 NLM Identifier: NCT01086280. Accessed 14 Jan 2014.